On October 8, 2009, the TB Alliance and Research!America co-sponsored a Capitol Hill Briefing in the US Senate chambers entitled, “Eliminating T...
Treatment shortening would be welcomed as a primary goal for future TB drug regimens, according to a new study from the Global Alliance for TB Drug De...
The TB Alliance recently announced the appointment of Marshall Burke, Ph.D. as the organization's Senior Vice President, External Affairs. D...
The Institute of Materia Medica (IMM), a member of the Chinese Academy of Sciences, was recently awarded a grant from the Chinese government to develo...
Each year, the Pacific Health Summit convenes global thought leaders to better understand how to harness scientific advances to tackle the world's pre...
Pharmaceutical giant Tibotec and the non-profit Global Alliance for TB Drug Development (TB Alliance) have teamed up to expedite the development of ...
[Seattle, WA] A new landmark collaboration between the Global Alliance for TB Drug Development (TB Alliance) a not-for-profit, product development par...
Healthcare company Johnson & Johnson (JNJ.N: Quote, Profile, Research, Stock Buzz) said on Wednesday it has joined with the nonprofit Global Allia...
TB Alliance, Tibotec, form partnership to take forward new drug Keith Alcorn Wednesday, June 17, 2009 Aidsmap.com Tibotec announced ...
NEW YORK (AP) - Drug developer Johnson & Johnson said Wednesday it will work with the Global Alliance for TB Drug Development as it continues deve...
Press Contact: press@tballiance.org
Falling Short: Ensuring Access to Simple, Safe and Effective First-Line Medicines for Tuberculosis
New TB Regimens: What Countries Want
Pathway to Patients
Policy on the Compassionate / Emergency Use of Experimental TB Alliance Drugs